Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine compatibility scheme for treating vivax malaria and use method of medicine compatibility scheme

A kind of medicine and day-to-day technology, which is applied in the direction of medical formula, drug combination, medical preparations containing active ingredients, etc., can solve the problems of short course of treatment, time and method of removing the medicine, etc.

Pending Publication Date: 2020-06-09
云南省寄生虫病防治所
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the results of clinical trials show that, compared with primaquine, there is no obvious advantage in other aspects except that the course of treatment is shorter (300mg once a day). What is more dangerous is that tafenoquine stays in the human body for several days. If there are patients with G6PD deficiency There is a hemolytic reaction to 8-aminoquinoline drugs, and the time and method of clinically clearing this drug are more difficult than primaquine, which poses a greater risk to malaria patients with G6PD deficiency

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine compatibility scheme for treating vivax malaria and use method of medicine compatibility scheme
  • Medicine compatibility scheme for treating vivax malaria and use method of medicine compatibility scheme
  • Medicine compatibility scheme for treating vivax malaria and use method of medicine compatibility scheme

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] 1. Case-control study

[0018] Such as figure 1 As shown, the ratio of people included in the case-control study (number of cases: number of controls) is 1:2, that is, one case selects 2 non-malarial people as controls. Based on 95% confidence level and 80% confidence level, the calculated minimum sample size is 162 in the case group and 325 in the control group. The case was a patient with a positive malaria parasite microscopic examination of a fever patient in a medical institution, and the control was a non-malarial person who went to the same institution for medical treatment (a negative malaria parasite microscopic examination). In order to exclude the influence of confounding factors such as age, gender and health status, the same gender, age (+ / - 5 years) and similar health status are matched. As a quality control, the blood samples of the case group and the control group were tested by PCR. Those who were negative in the PCR test of the case group and positive i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicine compatibility scheme for treating vivax malaria. The medicine compatibility scheme comprises the following medicine raw materials in a ratio: 17.5mg / kg of artemisinin, 7mg / kg of naphthoquine and 0.9mg / kg of primaquine. The invention further discloses a use method of the medicine compatibility scheme. The use method is that the artemisinin, the naphthoquine and the primaquine of the ratio are taken once per day respectively, and are taken separately for 3 days continuously. The scheme is short in treatment time, that is, can be completed within 3-5 days, and is high in compliance.

Description

Technical field [0001] The invention belongs to the field of therapeutic drugs, and specifically relates to a drug compatibility scheme for treating vivax malaria and a method of use thereof. Background technique [0002] The World Health Organization reported in 2019 that there are currently 31 countries around the world with malaria. In 2018, 228 million people contracted malaria and 405,000 died of malaria. There are 5 species of Plasmodium infecting humans. The most prevalent is Plasmodium vivax, the main species of Plasmodium in the WHO Americas, accounting for 75% of malaria cases. Both Plasmodium vivax and Plasmodium ovale form a dormant body in the liver for a long time and cause recurrence. Currently, the only antimalarials that can kill Plasmodium in the hepatic stage are 8-aminoquinolines, primaquinoline phosphate and tafenoquine. (Tafenoquine). It is extremely difficult to eradicate and block the transmission of vivax malaria. Experts believe that the current treatm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/366A61K31/4706A61P33/06
CPCA61K31/366A61K31/4706A61P33/06A61K2300/00Y02A50/30
Inventor 刘慧许建卫邓道伟尹一杰
Owner 云南省寄生虫病防治所
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com